Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2009 1
2013 1
2014 1
2015 1
2017 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of spondyloarthritis beyond TNF-alpha blockade.
Van den Bosch F, Deodhar A. Van den Bosch F, et al. Best Pract Res Clin Rheumatol. 2014 Oct;28(5):819-27. doi: 10.1016/j.berh.2014.10.019. Epub 2014 Nov 18. Best Pract Res Clin Rheumatol. 2014. PMID: 25488787 Review.
Even if treatment failure with TNF-blocking agents may be a relatively rare phenomenon, cases of primary non-responders, secondary loss-of-efficacy and intolerance, have been described. Results with abatacept, rituximab and tocilizumab - all effective in the treatment of r …
Even if treatment failure with TNF-blocking agents may be a relatively rare phenomenon, cases of primary non-responders, secondary loss-of-e …
[Established medications : new areas of application].
Kötter I, Henes JC. Kötter I, et al. Z Rheumatol. 2013 Nov;72(9):853-66. doi: 10.1007/s00393-013-1137-6. Z Rheumatol. 2013. PMID: 24193188 Review. German.
This is especially the case for rituximab and mycophenolate and to a lesser extent also for leflunomide, tumor necrosis factor (TNF) antagonists, tocilizumab and abatacept. Recently, rituximab was approved for severe granulomatosis with polyangiitis (GPA) and microscopic p …
This is especially the case for rituximab and mycophenolate and to a lesser extent also for leflunomide, tumor necrosis factor (TNF) antagon …
[Interstitial lung disease in rheumatic diseases - new therapeutic approaches].
Jakubczyc A, Neurohr C. Jakubczyc A, et al. Dtsch Med Wochenschr. 2020 Apr;145(7):470-473. doi: 10.1055/a-0985-5793. Epub 2020 Apr 1. Dtsch Med Wochenschr. 2020. PMID: 32236928 German.
Other investigated biologicals include Tocilizumab in SSc-ILD and Abatacept in pulmonary involvement in rheumatoid arthritis (RA-ILD). ...
Other investigated biologicals include Tocilizumab in SSc-ILD and Abatacept in pulmonary involvement in rheumatoid arthritis (RA-ILD) …
Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
Sepriano A, Regel A, van der Heijde D, Braun J, Baraliakos X, Landewé R, Van den Bosch F, Falzon L, Ramiro S. Sepriano A, et al. RMD Open. 2017 Jan 27;3(1):e000396. doi: 10.1136/rmdopen-2016-000396. eCollection 2017. RMD Open. 2017. PMID: 28176964 Free PMC article.
Ustekinumab and tofacitinib have shown positive results in phase 2/proof-of-concept trials; trials with apremilast, rituximab, interleukin (IL)-6 antagonists and abatacept have failed their primary end points. New (unknown) safety signals were not found in the trials but l …
Ustekinumab and tofacitinib have shown positive results in phase 2/proof-of-concept trials; trials with apremilast, rituximab, interleukin ( …
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL. Manders SH, et al. Arthritis Res Ther. 2015 May 22;17(1):134. doi: 10.1186/s13075-015-0630-5. Arthritis Res Ther. 2015. PMID: 25997746 Free PMC article. Clinical Trial.
RESULTS: Of 144 randomised patients, 5 were excluded and 139 started taking abatacept (43 patients), rituximab (46 patients) or a different TNFi (50 patients). ...However, our analysis revealed that rituximab therapy is significantly more cost-effective than both abatac …
RESULTS: Of 144 randomised patients, 5 were excluded and 139 started taking abatacept (43 patients), rituximab (46 patients) or a dif …
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.
Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC. Moreland LW, et al. Arthritis Rheum. 2002 Jun;46(6):1470-9. doi: 10.1002/art.10294. Arthritis Rheum. 2002. PMID: 12115176 Free article. Clinical Trial.